CDK4 and cancer: In addition, the LAR subgroup of TNBC showed a high sensitivity to CDK4/6 inhibitors (CDK4/6i) in vitro and in vivo, and CDK4/6i sensitize PIK3CA mutant cancers to PI3Ki [85].